19023496

Source:http://linkedlifedata.com/resource/pubmed/id/19023496

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists.
Subject	Predicate	Object	Context
pubmed-article:19023496	rdf:type	pubmed:Citation	lld:pubmed
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0087111	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0007131	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0246415	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C1135135	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0210657	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0680954	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0344211	lld:lifeskim
pubmed-article:19023496	lifeskim:mentions	umls-concept:C0205132	lld:lifeskim
pubmed-article:19023496	pubmed:issue	6	lld:pubmed
pubmed-article:19023496	pubmed:dateCreated	2008-11-21	lld:pubmed
pubmed-article:19023496	pubmed:abstractText	Evaluate costs and benefits of erlotinib as 2nd or 3rd line treatment of advanced or metastatic nonsmall cell lung cancer (NSCLC) versus docetaxel, pemetrexed and best supportive care.	lld:pubmed
pubmed-article:19023496	pubmed:commentsCorrections	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19023496	pubmed:language	eng	lld:pubmed
pubmed-article:19023496	pubmed:journal	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:19023496	pubmed:citationSubset	IM	lld:pubmed
pubmed-article:19023496	pubmed:status	MEDLINE	lld:pubmed
pubmed-article:19023496	pubmed:issn	0873-2159	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:PereiraCC	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:AraújoAA	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:ParentiFF	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:SilvaCC	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:PereiraHH	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:TeixeiraEE	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:Sotto-MayorRR	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:QueirogaHH	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:NegreiroFF	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:BarataFF	lld:pubmed
pubmed-article:19023496	pubmed:author	pubmed-author:AlmodôvarTT	lld:pubmed
pubmed-article:19023496	pubmed:issnType	Print	lld:pubmed
pubmed-article:19023496	pubmed:volume	14	lld:pubmed
pubmed-article:19023496	pubmed:owner	NLM	lld:pubmed
pubmed-article:19023496	pubmed:authorsComplete	Y	lld:pubmed
pubmed-article:19023496	pubmed:pagination	803-27	lld:pubmed
pubmed-article:19023496	pubmed:meshHeading	pubmed-meshheading:19023496...	lld:pubmed
pubmed-article:19023496	pubmed:articleTitle	An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.	lld:pubmed
pubmed-article:19023496	pubmed:affiliation	Francisco Gentil Portuguese Oncology Institute, Centro do Porto, Medical Oncology Unit, Porto, Portugal.	lld:pubmed
pubmed-article:19023496	pubmed:publicationType	Journal Article	lld:pubmed
pubmed-article:19023496	pubmed:publicationType	Research Support, Non-U.S. Gov't	lld:pubmed
http://linkedlifedata.com/r...	pubmed:referesTo	pubmed-article:19023496	lld:pubmed